LU91519I2 - "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr" - Google Patents

"Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"

Info

Publication number
LU91519I2
LU91519I2 LU91519C LU91519C LU91519I2 LU 91519 I2 LU91519 I2 LU 91519I2 LU 91519 C LU91519 C LU 91519C LU 91519 C LU91519 C LU 91519C LU 91519 I2 LU91519 I2 LU 91519I2
Authority
LU
Luxembourg
Prior art keywords
group
hydrogen
protecting group
doribaxr
doripenem
Prior art date
Application number
LU91519C
Other languages
English (en)
Original Assignee
Shionogi Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26374345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91519(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi Seiyaku Kk filed Critical Shionogi Seiyaku Kk
Publication of LU91519I2 publication Critical patent/LU91519I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
LU91519C 1991-08-20 2009-01-23 "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr" LU91519I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20797291 1991-08-20
JP3536692 1992-02-21

Publications (1)

Publication Number Publication Date
LU91519I2 true LU91519I2 (fr) 2009-03-23

Family

ID=26374345

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91519C LU91519I2 (fr) 1991-08-20 2009-01-23 "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"

Country Status (18)

Country Link
US (2) US5317016A (fr)
EP (1) EP0528678B1 (fr)
JP (1) JP2542773B2 (fr)
KR (1) KR100245671B1 (fr)
CN (2) CN1032257C (fr)
AT (1) ATE201413T1 (fr)
AU (1) AU652273B2 (fr)
CA (2) CA2203942C (fr)
DE (2) DE69231834T2 (fr)
DK (1) DK0528678T3 (fr)
ES (1) ES2159277T3 (fr)
GR (1) GR3036434T3 (fr)
LU (1) LU91519I2 (fr)
MX (1) MX9204805A (fr)
NL (1) NL300374I2 (fr)
NO (1) NO301371B1 (fr)
PT (1) PT528678E (fr)
TW (1) TW325475B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563264A (en) * 1993-02-10 1996-10-08 Shionogi & Co., Ltd. Preparation of βlactam compounds
DE69427100T2 (de) * 1993-02-10 2001-11-22 Shionogi & Co., Ltd. Herstellung von Beta-lactamverbindungen und Zwischenprodukte
CN1048248C (zh) * 1994-05-02 2000-01-12 盐野义制药株式会社 吡咯烷基硫基碳代青霉烯衍生物的结晶、含该结晶的冷冻干燥制剂及其制造方法
TW445265B (en) * 1996-11-25 2001-07-11 Meiji Seika Kaisha Carbapenem derivatives and antimicrobial agents
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
DK1270575T3 (da) * 2000-03-31 2006-01-16 Shionogi & Co Hidtil ukendt krystallinsk form af et pyrrolidylthiocarbapenemderivat
CA2415740A1 (fr) * 2000-07-19 2002-01-31 F. Hoffmann-La Roche Ag Derives de pyrrolidine utilises en tant qu'inhibiteurs de metalloprotease
EP1303507A1 (fr) * 2000-07-19 2003-04-23 F. Hoffmann-La Roche Ag Derives de pyrimidine
JP5328170B2 (ja) * 2001-05-10 2013-10-30 塩野義製薬株式会社 アセチルチオピロリジン誘導体の製法
JP5004355B2 (ja) * 2001-05-10 2012-08-22 塩野義製薬株式会社 アセチルチオピロリジン誘導体の製法
KR100473398B1 (ko) * 2002-08-31 2005-03-10 주식회사 하원제약 옥심기를 포함하는 피롤리딘 치환체를 가지는1-베타메틸카바페넴 유도체 및 그 제조방법
MXPA05008439A (es) * 2003-02-14 2005-10-19 Shionogi & Co Cristales de intermediarios de carbapenem.
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
KR20070061895A (ko) * 2004-10-08 2007-06-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규의 항균 약제
JP2008044847A (ja) * 2004-11-01 2008-02-28 Shionogi & Co Ltd カルバペネム合成体およびその製造法
US7932381B2 (en) * 2005-02-15 2011-04-26 Shionogi & Co., Ltd. Process for producing carbapenem derivative and intermediate crystal therefor
JP5019389B2 (ja) * 2005-02-15 2012-09-05 塩野義製薬株式会社 カルバペネム誘導体の製法およびその中間体結晶
WO2006117763A2 (fr) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Procede de preparation de doripeneme
TWI353855B (en) * 2005-05-26 2011-12-11 Shionogi & Co Method for preparing an aqueous solution of doripe
WO2007004028A2 (fr) * 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Procedes de preparation de penemes et de leurs intermediaires
CN100460389C (zh) * 2005-07-15 2009-02-11 成都地奥九泓制药厂 吡咯烷衍生物中间体及其制备方法和用途
JP2008303143A (ja) * 2005-08-19 2008-12-18 Shionogi & Co Ltd 連続化反応によるカルバぺネム誘導体の製法
EP1926732B1 (fr) 2005-09-05 2013-11-06 Ranbaxy Laboratories Limited Composes de carpapenem: operation amelioree de fabrication
CN100582106C (zh) * 2006-01-27 2010-01-20 上海医药工业研究院 一种吡咯烷硫基碳青霉烯衍生物的制备方法及其中间体
CN101479279B (zh) * 2006-06-28 2011-08-17 辉瑞产品公司 培南前药
CN101333219B (zh) * 2007-06-26 2010-10-13 山东轩竹医药科技有限公司 含有巯基吡咯烷甲酰胺苯烷基杂环的培南衍生物
CN101362757A (zh) * 2007-08-09 2009-02-11 山东轩竹医药科技有限公司 磺酰基取代的碳青霉烯类化合物
US20090075969A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched doripenem
PL2276762T3 (pl) * 2008-03-24 2015-06-30 Ranbaxy Laboratories Ltd Sposób wytwarzania jałowego doripenemu
KR20110049823A (ko) * 2008-07-30 2011-05-12 랜박시 래보러터리스 리미티드 카르바페넴 화합물의 제조 방법
WO2011048583A1 (fr) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Procédé pour la préparation de composés de carbapénème
CN102153553A (zh) * 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
CN102249970A (zh) * 2011-05-09 2011-11-23 黄山市歙县宏辉化工有限公司 一种多尼培南侧链的合成工艺
WO2013068910A1 (fr) 2011-11-08 2013-05-16 Ranbaxy Laboratories Limited Procédé de préparation de polymorphes de doripénème
CN102702201B (zh) * 2012-03-26 2013-12-25 深圳市海滨制药有限公司 一种多尼培南中间体化合物、其制备方法和用途以及多尼培南的制备方法
CN102964286B (zh) * 2012-12-06 2014-06-25 石家庄万尚医药科技有限公司 一种手性吡咯烷化合物及其制备方法
US11067210B2 (en) 2013-03-15 2021-07-20 Colder Products Company Low-spill coupling assembly
CN104496993B (zh) * 2014-09-18 2017-04-05 山东省生物医药科学院 一种碳青霉烯酯衍生物
KR20160007679A (ko) 2016-01-04 2016-01-20 제일약품주식회사 도리페넴의 신규한 결정형
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
MA43791A (fr) 2016-03-16 2018-11-28 Merck Sharp & Dohme Composés de carbapénème
JP7446424B2 (ja) * 2019-11-22 2024-03-08 スージョウ アーイェ ファーマシューティカル カンパニー リミテッド スルホニル尿素環置換単環式β－ラクタム系抗生物質
CN111960984B (zh) * 2020-09-11 2023-04-28 江西如益科技发展有限公司 一种合成多尼培南侧链中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153486C (da) * 1978-07-03 1988-11-28 Merck & Co Inc Analogifremgangsmaade til fremstilling af krystallinsk n-formimidoyl-thienamycin-monohydrat
US4260543A (en) * 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
JPS60233076A (ja) * 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
JPS62155279A (ja) * 1984-11-08 1987-07-10 Sumitomo Pharmaceut Co Ltd 新規なβ−ラクタム化合物
CA1281720C (fr) * 1984-11-08 1991-03-19 Makoto Sunagawa Composes de carbapenem et leur production
KR880006244A (ko) * 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
HUT63167A (en) * 1989-03-28 1993-07-28 Pfizer Process for producing antibacterial 2-carbapenem derivatives and pharmaceutical compositions comprising same as active ingredient
US5157125A (en) * 1989-09-25 1992-10-20 Pfizer Inc. Optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes
FI96311C (fi) * 1989-12-04 1996-06-10 Squibb Bristol Myers Co Menetelmä farmaseuttisesti käyttökelpoisten 6-(1-hydroksietyyli)-3-(substituoitu tio)-7-okso-1-atsabisyklo/3.2.0/hept-2-eeni-2-karboksyylihappojohdannaisten valmistamiseksi
IL99513A0 (en) * 1990-09-20 1992-08-18 Hoechst Ag Process for the preparation of carbapenem compounds
TW209220B (fr) * 1991-11-27 1993-07-11 Manyu Seiyaku Kk

Also Published As

Publication number Publication date
CA2076430A1 (fr) 1993-02-21
CA2203942C (fr) 2001-02-13
CN1034571C (zh) 1997-04-16
ES2159277T3 (es) 2001-10-01
DE69231834T2 (de) 2002-03-28
CN1071428A (zh) 1993-04-28
AU2109092A (en) 1993-02-25
EP0528678A1 (fr) 1993-02-24
CN1113233A (zh) 1995-12-13
MX9204805A (es) 1993-05-01
PT528678E (pt) 2001-08-30
JPH05294970A (ja) 1993-11-09
ATE201413T1 (de) 2001-06-15
NO923256D0 (no) 1992-08-19
CA2076430C (fr) 1997-12-23
CA2203942A1 (fr) 1993-02-21
DE69231834D1 (de) 2001-06-28
US5317016A (en) 1994-05-31
US5703243A (en) 1997-12-30
NL300374I2 (nl) 2009-06-02
KR930004306A (ko) 1993-03-22
KR100245671B1 (ko) 2000-05-01
JP2542773B2 (ja) 1996-10-09
AU652273B2 (en) 1994-08-18
CN1032257C (zh) 1996-07-10
EP0528678B1 (fr) 2001-05-23
DE122009000002I1 (de) 2009-05-20
NO301371B1 (no) 1997-10-20
NO923256L (no) 1993-02-22
GR3036434T3 (en) 2001-11-30
NL300374I1 (nl) 2009-04-01
TW325475B (en) 1998-01-21
DK0528678T3 (da) 2001-07-30

Similar Documents

Publication Publication Date Title
LU91519I2 (fr) "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"
KR100202474B1 (en) Novel tetrapeptide derivative
DE69231661D1 (de) Antifungizide trisubstituierte tetrahydrofurane
HK1011967A1 (en) Amide derivatives having anti-hyper cholesteremic activity their preparation and their therapeutic uses
IL94027A0 (en) Diaminoethylene compounds
HU9503090D0 (en) Novel bisoxadiazolidine derivative
DE68913835D1 (de) N-substituierte Amid-Derivate.
EP0601191A4 (en) Novel tetracyclic compound.
EP1043319A4 (fr) Nouveaux derives alkylamino
TW282470B (fr)
AU3386093A (en) Tetrahydrothiophene derivatives
DK0565059T3 (da) Indolderivat
TW216417B (en) Carboxylic acid derivative having retinoid type pharmacological activities